![conference banner](/images/conference-banner.jpeg)
Abstract
PDE5 inhibitors have been clearly established as first-line therapy for the treatment of erectile dysfunction (ED). Three PDE5 inhibitors – sildenafil (Viagra®), vardenafil (Levitra®) and tadalafil (Cialis®) - are currently approved by the FDA and the EMEA for use in ED, whereas sildenafil is also marketed under a different proprietary name (Revatio®) for the treatment of pulmonary arterial hypertension (PAH). A forth PDE5 inhibitor, udenafil (Zydena®), is currently marketed. In the present review the molecular basis and the mechanism of action of PDE5 inhibitors is discussed. In addition experimental and clinical data concerning their effects on different tissues, organs and systems is systematically reviewed and their possible beneficial action in numerous disorders is presented.
Keywords: PDE5 inhibitors, sildenafil, vardenafil, tadafil
Current Pharmaceutical Design
Title: PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile
Volume: 15 Issue: 30
Author(s): D. Kouvelas, A. Goulas, G. Papazisis, C. Sardeli and C. Pourzitaki
Affiliation:
Keywords: PDE5 inhibitors, sildenafil, vardenafil, tadafil
Abstract: PDE5 inhibitors have been clearly established as first-line therapy for the treatment of erectile dysfunction (ED). Three PDE5 inhibitors – sildenafil (Viagra®), vardenafil (Levitra®) and tadalafil (Cialis®) - are currently approved by the FDA and the EMEA for use in ED, whereas sildenafil is also marketed under a different proprietary name (Revatio®) for the treatment of pulmonary arterial hypertension (PAH). A forth PDE5 inhibitor, udenafil (Zydena®), is currently marketed. In the present review the molecular basis and the mechanism of action of PDE5 inhibitors is discussed. In addition experimental and clinical data concerning their effects on different tissues, organs and systems is systematically reviewed and their possible beneficial action in numerous disorders is presented.
Export Options
About this article
Cite this article as:
Kouvelas D., Goulas A., Papazisis G., Sardeli C. and Pourzitaki C., PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile, Current Pharmaceutical Design 2009; 15 (30) . https://dx.doi.org/10.2174/138161209789206971
DOI https://dx.doi.org/10.2174/138161209789206971 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Approaches to Minimize Infection Risk in Blood Banking and Transfusion Practice
Infectious Disorders - Drug Targets Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders
Current Medicinal Chemistry Effect of Autonomic Responses After Isometric Training at Different Intensities on Obese People
Current Hypertension Reviews Role of the Sympathetic Nervous Activity in Hypertension-Update in 2013
Current Hypertension Reviews Rapid Desensitization of Hypersensitivity Reactions to Chemotherapy Agents.
Current Drug Safety Renal Microcirculation and Calcium Channel Subtypes
Current Hypertension Reviews Targeting Soluble Epoxide Hydrolase for Inflammation and Pain - An Overview of Pharmacology and the Inhibitors
Inflammation & Allergy - Drug Targets (Discontinued) Hydrolases in Organic Chemistry. Recent Achievements in the Synthesis of Pharmaceuticals
Current Organic Chemistry Role of Infrared Spectroscopy in Medicinal Plants Research in Pakistan
Current Bioactive Compounds Is Peri-Operative Isolated Systolic Hypertension (ISH) a Cardiac Risk Factor?
Current Cardiology Reviews Rationale of Hyperbaric Oxygenation in Cerebral Vascular Insult
Current Vascular Pharmacology Review of Rational Approaches to the Treatment of Pain Management-Role forOpioids Therapies
Current Drug Therapy Blood Pressure as a Therapeutic Target in Stroke
Current Topics in Medicinal Chemistry Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Current Cancer Drug Targets Pharmacological Treatment of Hypertension in Pregnancy
Current Pharmaceutical Design An Efficient and Environmentally Benign Access Towards Synthesis of Novel 1,2,3-Triazolyl-pyrazoline Hybrids
Letters in Organic Chemistry Pharmacological Risk Factors for Delirium after Cardiac Surgery: A Review
Current Neuropharmacology Investigating Drug-induced Mitochondrial Toxicity: A Biosensor to Increase Drug Safety?
Current Drug Safety TRP Channels: Emerging Links Between Ca2+, Kidney and Hypertension
Current Hypertension Reviews Functions of Third Extracellular Loop and Helix 8 of Family B GPCRs Complexed with RAMPs and Characteristics of their Receptor Trafficking
Current Protein & Peptide Science